Refine Search

Search Results -

Terms	Documents
L5 and cardiolipin	3

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L6

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Wednesday, December 07, 2005 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L6	L5 and cardiolipin	3	L6
L5	mixture adj5 (multilamellar adj3 unilamellar)	4	L5
L4	L3 and $tocopherol	2	L4
L3	L2 and trehalose	8	L3
L2	aminoglycoside same liposome same dehydrat$	8	L2
L1	vinorelbine same (cancer or lymphoma or tumor)	286	L1

END OF SEARCH HISTORY

First Hit Fwd Refs Previous Doc Next Doc Go to Doc#

Generate Collection Print

L2: Entry 1 of 8 File: USPT Jul 13, 1999

DOCUMENT-IDENTIFIER: US 5922350 A
TITLE: Methods of dehydrating, storing and rehydrating liposomes

Detailed Description Text (8):
So that the liposomes will survive the dehydration process without losing a substantial portion of their internal contents, it is important that one or more protective sugars be available to interact with the liposome membranes and keep them intact as the water in the system is removed. A variety of sugars can be used, including such sugars as trehalose, maltose, sucrose, glucose, lactose, and dextran. In general, disaccharide sugars have been found to work better than monosaccharide sugars, with the disaccharide sugars trehalose and sucrose being most effective. Other more complicated sugars can also be used. For example, aminoglycosides, including streptomycin and dihydrostreptomycin, have been found to protect liposomes during dehydration.

Previous Doc Next Doc Go to Doc#

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 8 of 8 returned.

☐ 1. Document ID: US 5922350 A

Using default format because multiple data bases are involved.

L2: Entry 1 of 8 File: USPT Jul 13, 1999

US-PAT-NO: 5922350
DOCUMENT-IDENTIFIER: US 5922350 A

TITLE: Methods of dehydrating, storing and rehydrating liposomes

DATE-ISSUED: July 13, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Janoff; Andrew S.	Yardley	PA		
Cullis; Pieter R.	Vancouver			CA
Bally; Marcel B.	Vancouver			CA
Fountain; Michael W.	Griggstown	NJ		
Ginsberg; Richard S.	Monroe	NJ		
Hope; Michael J.	Vancouver			CA
Madden; Thomas D.	Vancouver			CA
Schieren; Hugh P.	Yardley	PA		
Jablonski; Regina L.	Trenton	NJ		

US-CL-CURRENT: 424/450; 264/4.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 2. Document ID: US 5837279 A

L2: Entry 2 of 8 File: USPT Nov 17, 1998

US-PAT-NO: 5837279
DOCUMENT-IDENTIFIER: US 5837279 A

TITLE: Encapsulation of ionizable agents in liposomes

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY

Janoff; Andrew S.	Yardley	PA	
Cullis; Pieter R.	Vancouver		CA
Bally; Marcel B.	Vancouver		CA
Fountain; Michael W.	Griggstown	NJ	
Ginsberg; Richard S.	Monroe	NJ	
Hope; Michael J.	Vancouver		CA
Madden; Thomas D.	Vancouver		CA
Schieren; Hugh P.	Yardley	PA	
Jablonski; Regina L.	Trenton	NJ	

US-CL-CURRENT: 424/450; 264/4.1, 264/4.3, 264/4.6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 3. Document ID: US 5800833 A

L2: Entry 3 of 8 File: USPT Sep 1, 1998

US-PAT-NO: 5800833
DOCUMENT-IDENTIFIER: US 5800833 A

TITLE: Method for loading lipid vesicles

DATE-ISSUED: September 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hope; Michael	Vancouver			CA
Cullis; Pieter R.	Vancouver			CA
Fenske; David	Surrey			CA
Wong; Kim	Vancouver			CA

US-CL-CURRENT: 426/450; 264/4.1, 264/4.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 4. Document ID: US 5785987 A

L2: Entry 4 of 8 File: USPT Jul 28, 1998

US-PAT-NO: 5785987
DOCUMENT-IDENTIFIER: US 5785987 A

TITLE: Method for loading lipid vesicles

DATE-ISSUED: July 28, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY

Hope; Michael	Vancouver	CA
Cullis; Pieter R.	Vancouver	CA
Fenske; David B.	Surrey	CA
Wong; Kim F.	Vancouver	CA

US-CL-CURRENT: 424/450; 264/4.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 5. Document ID: US 5736155 A

L2: Entry 5 of 8 File: USPT Apr 7, 1998

US-PAT-NO: 5736155
DOCUMENT-IDENTIFIER: US 5736155 A
** See image for Certificate of Correction **

TITLE: Encapsulation of antineoplastic agents in liposomes

DATE-ISSUED: April 7, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bally; Marcel B.	Vancouver			CA
Cullis; Pieter R.	Vancouver			CA
Hope; Michael J.	Vancouver			CA
Madden; Thomas D.	Vancouver			CA
Mayer; Lawrence D.	Vancouver			CA

US-CL-CURRENT: 424/450; 264/4.1, 264/4.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 6. Document ID: US 5578320 A

L2: Entry 6 of 8 File: USPT Nov 26, 1996

US-PAT-NO: 5578320
DOCUMENT-IDENTIFIER: US 5578320 A

TITLE: Method of dehydrating liposomes using protective sugars

DATE-ISSUED: November 26, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Janoff; Andrew S.	Yardley	PA		
Cullis; Pieter R.	Vancouver			CA
Bally; Marcel B.	Vancouver			CA

Fountain; Michael W.	Griggstown	NJ	
Ginsberg; Richard S.	Monroe	NJ	
Hope; Michael J.	Vancouver		CA
Madden; Thomas D.	Vancouver		CA
Schieren; Hugh P.	Yardley	PA	
Jablonski; Regina L.	Trenton	NJ	

US-CL-CURRENT: 424/450; 264/4.1, 264/4.3, 264/4.6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 7. Document ID: US 5077056 A

L2: Entry 7 of 8 File: USPT Dec 31, 1991

US-PAT-NO: 5077056
DOCUMENT-IDENTIFIER: US 5077056 A

TITLE: Encapsulation of antineoplastic agents in liposomes

DATE-ISSUED: December 31, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bally; Marcel B.	Vancouver			CA
Cullis; Pieter R.	Vancouver			CA
Hope; Michael J.	Vancouver			CA
Madden; Thomas D.	Vancouver			CA
Mayer; Lawrence D.	Vancouver			CA

US-CL-CURRENT: 424/450; 436/829

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 8. Document ID: US 4880635 A

L2: Entry 8 of 8 File: USPT Nov 14, 1989

US-PAT-NO: 4880635
DOCUMENT-IDENTIFIER: US 4880635 A
** See image for Certificate of Correction **
** See image for Reexamination Certificate **

TITLE: Dehydrated liposomes

DATE-ISSUED: November 14, 1989

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY

Janoff; Andrew S.	Yardley	PA	
Cullis; Pieter R.	Vancouver		CA
Bally; Marcel B.	Vancouver		CA
Fountain; Michael W.	Griggstown	NJ	
Ginsberg; Richard S.	Monroe	NJ	
Hope; Michael J.	Vancouver		CA
Madden; Thomas D.	Vancouver		CA
Schieren; Hugh P.	Yardley	PA	
Jablonski; Regina L.	Trenton	NJ	

US-CL-CURRENT: 424/450

Terms	Documents
aminoglycoside same liposome same dehydrat$	8

L4: Entry 1 of 2 File: USPT Sep 1, 1998

DOCUMENT-IDENTIFIER: US 5800833 A
TITLE: Method for loading lipid vesicles

Detailed Description Text (27):
To ensure that the liposomes will survive the dehydration process without losing a substantial portion of their internal contents, it is important that one or more protective sugars be available to interact with the lipid vesicle membranes and keep them intact as the water in the system is removed. A variety of sugars can be used, including such sugars as trehalose, maltose, sucrose, glucose, lactose, and dextran. In general, disaccharide sugars have been found to work better than monosaccharide sugars, with the disaccharide sugars trehalose and sucrose being most effective. Other more complicated sugars can also be used. For example, aminoglycosides, including streptomycin and dihydrostreptomycin, have been found to protect lipid vesicles during dehydration.

Detailed Description Text (49):
Pharmaceutical compositions comprising the liposomes of the invention are prepared according to standard techniques and further comprise a pharmaceutically acceptable carrier. Generally, normal saline will be employed as the pharmaceutically acceptable carrier. Other suitable carriers include, e.g., water, buffered water, 0.4% saline, 0.3% glycine, and the like, including glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, etc. These compositions may be sterilized by conventional, well known sterilization techniques. The resulting aqueous solutions may be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc. Additionally, the liposome suspension may include lipid-protective agents which protect lipids against free-radical and lipid-peroxidative damages on storage. Lipophilic free-radical quenchers, such as alphatocopherol and water-soluble iron-specific chelators, such as ferrioxamine, are suitable.

Refine Search

Search Results -

Terms	Documents
L3 and $tocopherol	2

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L4

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Wednesday, December 07, 2005 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L4	L3 and $tocopherol	2	L4
L3	L2 and trehalose	8	L3
L2	aminoglycoside same liposome same dehydrat$	8	L2
L1	vinorelbine same (cancer or lymphoma or tumor)	286	L1

END OF SEARCH HISTORY

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 6461637 B1

Using default format because multiple data bases are involved.

L5: Entry 1 of 4 File: USPT Oct 8, 2002

US-PAT-NO: 6461637
DOCUMENT-IDENTIFIER: US 6461637 B1

TITLE: Method of administering liposomal encapsulated taxane

DATE-ISSUED: October 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rahman; Aquilur	Long Grove	IL		

US-CL-CURRENT: 424/450; 514/449, 514/510

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 2. Document ID: US 6146659 A

L5: Entry 2 of 4 File: USPT Nov 14, 2000

US-PAT-NO: 6146659
DOCUMENT-IDENTIFIER: US 6146659 A

TITLE: Method of administering liposomal encapsulated taxane

DATE-ISSUED: November 14, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rahman; Aquilur	Long Grove	IL		

US-CL-CURRENT: 424/450; 514/449, 514/510

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 3. Document ID: US 5676928 A

L5: Entry 3 of 4 File: USPT Oct 14, 1997

US-PAT-NO: 5676928
DOCUMENT-IDENTIFIER: US 5676928 A

TITLE: Liposomes

DATE-ISSUED: October 14, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klaveness; Jo	Oslo			NO
Berg; Arne	Sandvika			NO
Jacobsen; Trond Vegard	Oslo			NO
Rongved; Pal	Nesoddtangen			NO
Ege; Thorfinn	Tranby			NO
Kikuchi; Hiroshi	Tokyo			JP
Yachi; Kiyoto	Tokyo			JP

US-CL-CURRENT: 424/9.321; 424/450, 424/9.4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 4. Document ID: US 5648090 A

L5: Entry 4 of 4 File: USPT Jul 15, 1997

US-PAT-NO: 5648090
DOCUMENT-IDENTIFIER: US 5648090 A
** See image for Certificate of Correction **

TITLE: Liposome encapsulated toxol and a method of using the same

DATE-ISSUED: July 15, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rahman; Aquilur	Gaithersburg	MD		
Rafaeloff; Rafael	Tel-Aviv			IL
Husain; Syed Rafat	Gaithersburg	MD		

US-CL-CURRENT: 424/450

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents

mixture adj5 (multilamellar adj3 unilamellar) 4

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 6461637 B1

Using default format because multiple data bases are involved.

L6: Entry 1 of 3 File: USPT Oct 8, 2002

US-PAT-NO: 6461637
DOCUMENT-IDENTIFIER: US 6461637 B1

TITLE: Method of administering liposomal encapsulated taxane

DATE-ISSUED: October 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rahman; Aquilur	Long Grove	IL		

US-CL-CURRENT: 424/450; 514/449, 514/510

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 2. Document ID: US 6146659 A

L6: Entry 2 of 3 File: USPT Nov 14, 2000

US-PAT-NO: 6146659
DOCUMENT-IDENTIFIER: US 6146659 A

TITLE: Method of administering liposomal encapsulated taxane

DATE-ISSUED: November 14, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rahman; Aquilur	Long Grove	IL		

US-CL-CURRENT: 424/450; 514/449, 514/510

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 3. Document ID: US 5648090 A

L6: Entry 3 of 3 File: USPT Jul 15, 1997

US-PAT-NO: 5648090
DOCUMENT-IDENTIFIER: US 5648090 A
** See image for Certificate of Correction **

TITLE: Liposome encapsulated toxol and a method of using the same

DATE-ISSUED: July 15, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rahman; Aquilur	Gaithersburg	MD		
Rafaeloff; Rafael	Tel-Aviv			IL
Husain; Syed Rafat	Gaithersburg	MD		

US-CL-CURRENT: 424/450

Terms	Documents
L5 and cardiolipin	3

Refine Search

Search Results -

Terms	Documents
vinorelbine same (cancer or lymphoma or tumor)	286

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L1

Refine Search

Recall Text Clear Interrupt

Search History

DATE: Wednesday, December 07, 2005 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L1	vinorelbine same (cancer or lymphoma or tumor)	286	L1

END OF SEARCH HISTORY

First Hit Fwd Refs Previous Doc Next Doc Go to Doc#

Generate Collection Print

L1: Entry 94 of 286 File: USPT Apr 20, 2004

DOCUMENT-IDENTIFIER: US 6723338 B1
** See image for Certificate of Correction **
TITLE: Compositions and methods for treating lymphoma

Brief Summary Text (15):
In another embodiment, the mammal is a human. In another embodiment, the mammal has previously undergone at least one chemotherapy treatment. In another embodiment, the chemotherapy treatment comprised administration of a free-form vinca alkaloid, such as vincristine, vinblastine, vindesine, or vinorelbine. In other embodiments, the chemotherapy treatment included an anthracycline-containing combination therapy. In one such embodiment, the anthracycline was doxorubicin. In another embodiment, the mammal has exhibited a partial or complete response to the chemotherapy prior to a relapse of the cancer. In another embodiment, the relapse is a second relapse.

Previous Doc Next Doc Go to Doc#

L1: Entry 205 of 286 File: USPT Apr 2, 2002

US-PAT-NO: 6365735
DOCUMENT-IDENTIFIER: US 6365735 B1

TITLE: Vinca-alkaloid derivatives and preparation method

DATE-ISSUED: April 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rool; Patrice	Brunoy			FR

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Roowin S.A.	Paris			FR	03

APPL-NO: 09/701502 [PALM]
DATE FILED: January 8, 2001

FOREIGN-APPL-PRIORITY-DATA:

COUNTRY	APPL-NO	APPL-DATE
FR	98 06895	June 2, 1998

PCT-DATA:

APPL-NO	DATE-FILED	PUB-NO	PUB-DATE	371-DATE	102(E)-DATE
PCT/FR99/01289	June 2, 1999	WO99/62912	Dec 9, 1999	Jan 8, 2000	Jan 8, 2000

INT-CL: [07] C07 D 519/04

US-CL-ISSUED: 540/478; 540/579
US-CL-CURRENT: 540/478; 540/579

FIELD-OF-SEARCH: 540/478, 540/579

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

	PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
☐	4737586	April 1988	Potier et al.	540/478
☐	5037977	August 1991	Tan et al.	

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	CLASS
38 01 450	August 1988	DE	
38 26 412	February 1989	DE	
WO 89/12056	December 1989	WO	
WO 89 12056	December 1989	WO	

OTHER PUBLICATIONS

Richard J. Sundberg et al.; "Mechanistic aspects of the formation of anhydrovinblastine by Potier-Polonovski oxidative coupling of catharanthine and vindoline. Spectroscopic observation and chemical reactions of intermediates" Tetrahedron., vol. 48, No. 2,--Jan. 10, 1992; pp. 277-296, XP002083507 Oxford GB--the whole document.
Richard J. Sundberg et al.; "Oxidative fragmentation of catharanthine by dichlorodicyanoquinone"; Journal of Organic Chemistry,--Mar. 1, 1991; pp. 1689-1692, XP002083508 Easton US --the whole document.
Richard J. Sundberg et al.; "Photoactivated C16-C21 fragmentation of catharanthine" Tetrahedron Letters, vol. 32, No. 26, Jun. 24, 1992, pp. 3035-3038 XP002083509 Oxford GB--the whole document.
E. Gunic et al., "Electrochemical Synthesis of Anhydrovinblastine", J. Chem. Soc., Chem. Commun., 1993, pp. 1496-1497.
I. Tabakovic et al., "Anodic Fragmentation of Catharanthine and Coupling with Vindoline. Formation of Anhydrovinblastine", J. Org. Chem., 1997, vol. 62, pp 947-953.
J. Vucovik et al., "Production of 3',4'-anhydrovinblastine: a Unique Chemical Synthesis", Pergamon Journals Ltd., 1988, vol. 44, pp. 325-331.

ART-UNIT: 1624

PRIMARY-EXAMINER: Raymond; Richard L.

ASSISTANT-EXAMINER: Balasubramanian; Venkataraman

ATTY-AGENT-FIRM: Henderson & Sturm LLP

ABSTRACT:

The invention concerns a novel method for preparing vinca-alkaloids by reacting a catharantine-type product and a vindoline-type product, characterized in that it consists in selecting the reaction conditions such that the product is oxidized.

24 Claims, 0 Drawing figures

Previous Doc Next Doc Go to Doc#

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTAU153GXK

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	4	OCT 03	MATHDI removed from STN
NEWS	5	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS	6	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS	7	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS	8	OCT 27	Free KWIC format extended in full-text databases
NEWS	9	OCT 27	DIOGENES content streamlined
NEWS	10	OCT 27	EPFULL enhanced with additional content
NEWS	11	NOV 14	CA/CAplus - Expanded coverage of German academic research
NEWS	12	NOV 30	REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data
NEWS	13	DEC 05	CASREACT(R) - Over 10 million reactions available

NEWS EXPRESS DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:04:47 ON 07 DEC 2005

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'STNGUIDE' ENTERED AT 07:04:56 ON 07 DEC 2005

```
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec  2, 2005 (20051202/UP).

=> FIL HOME
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.06       0.27

FILE 'HOME' ENTERED AT 07:05:02 ON 07 DEC 2005

=> S FILE CAPLUS
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.48

FILE 'CAPLUS' ENTERED AT 07:05:30 ON 07 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Dec 2005  VOL 143 ISS 24
FILE LAST UPDATED: 6 Dec 2005  (20051206/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s vinorelbine (p) liposome
          1367 VINORELBINE
         33247 LIPOSOME
L1          19 VINORELBINE (P) LIPOSOME

=> l1 and cardiolipin
L1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l1 and cardiolipin
          4597 CARDIOLIPIN
L2           1 L1 AND CARDIOLIPIN

=> d 1

L2   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2003:173434  CAPLUS
DN   138:210345
TI   Vinorelbine compositions and methods of use
IN   Zhang, Jia-Ai; Ahmad, Imran
PA   Neopharm, Inc., USA
```

SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003018018	A2	20030306	WO 2002-US26907	20020823
	WO 2003018018	A3	20030501		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004228911	A1	20041118	US 2004-786866	20040224
PRAI	US 2001-314959P	P	20010824		
	WO 2002-US26907	A1	20020823		

=> d l1 1-19 ab

L1 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB A process for the large scale production of a liposome suspension, in which three selected lipid compds. in a predetd. ratio are dissolved in an alc. solvent to form a mixture, which, in turn, is directly admixed with an aqueous ammonium sulfate solution in a predetd. ratio. The resultant mixture is subjected to a pore-extrusion treatment, followed by dialyzing the pore-extruded mixture with a 5% to 15% sucrose aqueous solution, such that a liposome suspension containing liposome particles suspended in the liposome suspension is obtained. The thus obtained liposome suspension can be used to encapsulate a selected drug, in particular doxorubicin.

L1 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB **Vinorelbine** (VRL) is a particularly lipophilic member of the vinca alkaloids which, as a class of drugs, exhibit improved cytotoxicity and therapeutic activity through increased duration of exposure. Here, we describe and optimize a sphingomyelin/cholesterol (SM/Chol) **liposome** formulation of VRL to maximize in vivo drug retention, plasma circulation time, and therapeutic activity. VRL was efficiently encapsulated (>90%) into 100 nm liposomes using an ionophore-mediated loading method. VRL retention in SM/Chol liposomes after i.v. injection in mice was dependent on drug-to-lipid ratio (D/L), with higher D/L ratios exhibiting increased drug retention (0.3>0.2>0.1, weight/weight) and improved pharmacokinetics. Cryo-electron microscopic examination of a high D/L ratio formulation indicated that the intravesicular regions of these liposomes were electron dense compared with empty liposomes. The optimized, high D/L ratio SM/Chol VRL formulation showed promising activity against s.c. B16 melanoma tumors compared with VRL or SM/Chol formulations of vincristine or vinblastine. Finally, the stability of the formulation was excellent (<5% drug leakage, >99% intact VRL, no changes in **liposome** size after 1 yr at 2-8°). The optimized drug retention properties of the SM/Chol formulation of VRL, combined with its promising antitumor activity and pharmaceutical stability, make this formulation an excellent candidate for future clin. development.

L1 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB A comparative study of the loading and retention properties of three structurally very closely related vinca alkaloids (vincristine, vinorelbine and vinblastine) in liposomal formulations has been performed. All three vinca alkaloids showed high levels of encapsulation when accumulated into egg sphingomyelin/cholesterol vesicles in response to a transmembrane pH gradient generated by the use of the ionophore A23187 and encapsulated MgSO4. However, despite the close similarities of their structures the different vinca drugs exhibited very different release

behavior, with vinblastine and vinorelbine being released faster than vincristine both in vitro and in vivo. The differences in loading and retention can be related to the lipophilicity of the drugs tested, where the more hydrophobic drugs are released more rapidly. It was also found that increasing the drug-to-lipid ratio significantly enhanced the retention of vinca alkaloids when the ionophore-based method was used for drug loading. In contrast, drug retention was not dependent on the initial drug-to-lipid ratio for vinca drugs loaded into liposomes containing an acidic citrate buffer. The differences in retention can be explained on the basis of differences in the phys. state of the drug inside the liposomes. The drug-to-lipid ratio dependence of retention observed for liposomes loaded with the ionophore technique may provide a way to improve the retention characteristics of liposomal formulations of vinca drugs.

L1 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the co-administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, with a topoisomerase II inhibitor, e.g., etoposide or NK-611, to a mammal with a lymphoma or a sarcoma.

L1 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB The present invention relates to the synthesis and biol. application of piperidinoyl carboxylic acid integrin antagonists affinity moiety of formula (I) and formula (II) [W = -C0-6alkyl(R1), -C1-6 alkyl(R1a), -C0-6 alkylaryl(R1,R8), -C0-6 alkylheterocyclyl(R1,R8), etc.; R1 = H, (un)substituted NH2, -heterocyclyl-(R8), -heteroaryl-(R8); R1a = -C(R4)(:NR4), -C(:NR4)-N(R4)2, -C(:NR4)-N(R4)(R6), -C(:N-R4)-N(R4)-C(O)-R4, etc.; R4 = H, C1-8 alkyl; R8 = H, -C1-8 alkyl(R9), -CHO, -CO-C1-8 alkyl(R9), -CONH2, etc.; R9 = H, C1-8 alkoxy, each (un)substituted NH2, CONH2, or SO2NH2, CHO, etc.; q = 0-3; R2 = -C1-8 alkyl(R7)(R11), -C2-8 alkenyl(R7)(R11), -C2-8 alkynyl(R7)(R11), -cycloalkyl-(R7)(R11), -heterocyclyl-(R8)(R12), etc.; R7 = H, -C1-8 alkoxy(R9), each (un)substituted NH2 or CONH2, CHO, -CO-C1-8 alkyl(R9), etc.; R11 = -C1-8 alkyl(R14), -O-C1-8 alkyl(R14), -NH-C1-8 alkyl(R14), -S-C1-8 alkyl(R14), etc.; R12 = -C1-8 alkyl(R14), -O-C1-8 alkyl(R14), -NH-C1-8 alkyl(R14), etc.; R14 when R11 and R12 terminates with a C(:O) is selected from the group consisting of H, OH, -OC1-4 alkyl, and NH2; otherwise R14 = OH, SH, CO2H , CO2-1-4 alkyl; Z = OH, (un)substituted NH2, -O-C1-8 alkyl, O-C1-8 alkyl-OH, -O-C1-8 alkyl-C1-8 alkoxy, etc.] and pharmaceutically acceptable salts, racemic mixts., and enantiomers thereof. These affinity moieties maybe used with imaging agents or liposomes to target cells that express the αvβ3, αvβ5, or αvβ6 integrin receptors. For example, an enantiomer of 6-methoxy-β-[[1-[1-oxo-3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-4-piperidinyl]methyl]-3-pyridinepropanoic acid inhibited the binding of vitronectin to αvβ3, αvβ5, and αIIbβ3 receptors with IC50 of 0.0003±0.00002, 0.0042±0.0018, and 1.83±0.57 μM, resp.

L1 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB Introduction: This study was designed to define the maximum tolerated dose of pegylated liposomal doxorubicin (Doxil) and multiday vinorelbine (VNB), without and with prophylactic filgrastim, and to identify antineoplastic effect. Patients and Methods: Patients with resistant cancers were treated with Doxil 50 mg/m2 every four weeks, and with VNB 15 mg/m2 on the same day. The VNB dose escalations were accomplished in subsequent patient cohorts by adding VNB doses on consecutive days. When the maximum tolerated dose (MTD) of VNB with Doxil was defined, prophylactic filgrastim was added to define a second MTD. Results: Of 29 patients entered, two had early adverse events, and 27 received at least one full cycle with at least one month follow-up. The MTD of VNB, combined with Doxil 50 mg/m2, was 15 mg/m2 on day 1, with neutropenia as the dose-limiting toxicity. With prophylactic filgrastim, the MTD was 15 mg/m2 daily for two days, with neutropenia and stomatitis as dose-limiting toxicities. Palmar plantar erythrodysesthesia occurred frequently, usually after the third cycle. Objective responses were documented in six patients, all of whom received multiday VNB. Conclusion: Doxil 50 mg/m2 on day 1 of a 28-day cycle can be safely combined with VNB 15 mg/m2 day 1,

or with VNB 15 mg/m2 days 1 and 2 with filgrastim prophylaxis. Antineoplastic activity was observed in this heavily pretreated population. Future studies of Doxil 35-40 mg/m2 with multiday VNB may be worthwhile, especially in metastatic breast cancer.

L1 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB This exptl. article provides data concerning of the encapsulation of vinorelbine (VNR) in various liposomal composition which was achieved using different ammonium and sodium salts. The amount of VNR trapped inside the liposomes and the rate of release at 2 °C and 37 °C in buffer and in rat plasma up to 50% by volume at 37 °C, 45 °C and 55 °C (thermosensitivity liposomes), was determined by UV-vis spectrometry. VNR was encapsulated into Sterically Stabilized Liposomes (SSL) with high efficiency at 98%, using ammonium sulfate pH gradient method. The results concerning the rate of release, suggest that the lipid composition of the liposomes, the external solution (buffer or plasma) as well as the temperature play an important role of the drug release from the liposomes. Vincristine (VNC) was also studied in parallel expts. for comparative reasons.

L1 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB This invention provides compns. and methods for the treatment of tumors in a mammal. In particular, the invention provides **liposome** -encapsulated vinca alkaloids, e.g., **vinorelbine**, and methods of treating a mammal using such compns.

L1 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB The present invention is for novel compns. and methods for treating cancer, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compns. of the present invention include **liposome** entrapped **vinorelbine** in which the **liposome** can contain any of a variety of neutral or charged **liposome**-forming compds. and cardiolipin. The liposomes of the present invention can be either multilamellar vesicles or unilamellar vesicles, as desired. **Vinorelbine** liposomes having encapsulation efficinecy of 80% were prepared

L1 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB In this phase II study, 23 patients with metastatic breast cancer were treated with a combination of Caelyx (40 mg/m2 on day 1) and vinorelbine (20 mg/m2 on days 1 and 8) every 4 wk. According to the statistical design, enrollment was closed after the first stage due to the low response rate observed (four partial remissions, 12 stabilizations). Toxicity was acceptable, however, grade 3-4 neutropenia was not negligible. Our study does not support the development of this combination in advanced breast cancer.

L1 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB The present invention provides methods and compns. for the treatment and prevention of any of a large number of diseases and conditions with an angiogenic component, e.g., cancer. The present invention is based upon the discovery that liposome-encapsulated chemotherapeutic agents, such as alkaloids (e.g., vinca alkaloids such as vincristine), are surprisingly effective at treating such diseases or conditions when administered at a higher frequency than those used with conventional administration strategies. Such methods can be used to treat diseases such as cancer even when the cancer comprises cells that are resistant to the chemotherapeutic alkaloid. The liposome encapsulation of the chemotherapeutic agents, e.g., alkaloids, imparts dramatic improvements in the stability, biodistribution, and delivery of the agents, thereby allowing more efficacious and convenient administration to a patient with any of the herein-described diseases or conditions.

L1 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve (i) contacting the cell with a reporter non-covalently coupled to a ligand; (ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and (iii) detecting the reporter within said cell (if

any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized.

L1 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB A review. Efforts to improve further therapy for advanced ovarian carcinoma currently focus on addition of a third active agent to front-line chemotherapy. Three agents with activity against disease clin. resistant to paclitaxel and the platinum compds. are of greatest interest: gemcitabine, topotecan, and **liposome**-encapsulated doxorubicin. Three strategies to add a third agent include a triplet regimen that adds a third agent concurrently; a sequential doublet regimen giving three to four cycles of the new agent plus a platinum followed by three to four cycles of paclitaxel plus a platinum; and sequential single agents consisting of three to four cycles of the new agent with three to four cycles each of paclitaxel and a platinum. Gemcitabine in combination with another agent has been evaluated to develop doublet regimens for the second of these three strategies. Combinations both feasible and active include gemcitabine plus cisplatin or carboplatin, gemcitabine plus paclitaxel, gemcitabine plus topotecan, gemcitabine plus **liposome** -encapsulated doxorubicin, gemcitabine plus **vinorelbine**, and gemcitabine plus treosulfan. The combinations of gemcitabine plus a platinum compound appear most promising with synergism suggested by the data. A gemcitabine/carboplatin doublet for four cycles followed by four cycles of paclitaxel/carboplatin is currently under evaluation in a randomized phase III trial (Gynecol. Oncol. Group [GOG] protocol 0182).

L1 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB The concentration-time profiles of Doxorubicin (DOXO) from day 0 to day 21 after i.v. infusion of 25 or 30 mg/m2 doxorubicin HCl stealth liposomes (Caelyx) were investigated in 9 patients receiving combination polychemotherapy with cyclophosphamide, vinorelbine and prednisone. Peak serum concns. occurred from 0.04 to 4.0 days after infusion (mean tmax = 1.79±1.55 d) with a mean cmax of 4595±2849 ng/mL. A total amount of 12.84±2.47 mg liposomal DOXO in the plasma volume (Vp = 2794+537 mL) could be estimated at tmax (=27% of the mean dose of 47.6 mg). Stealth liposomes were eliminated slowly from the blood with a mean t1/2el of 1.9+0.5 days (MRT was 4.6+2.5 days). AUClast values ranged from 8070 to 33446 ng/mL*d (mean 10987±9339 ng/mL*d). The low plasma clearance (Cltot = 4681±2835 mL/day) and the small volume of distribution (Vz = 11.7±6.31) suggested that stealth-liposomes were stable in the blood at least for 14 days. Polychemotherapy with Hyper-CCVP schedule did not alter the stability of stealth liposomes, but peak levels of DOXO seemed to be somewhat lower compared to regression anal. of literature data (cmax vs. dosage range from 20 to 60 mg/m2). Due to clast occurring between day 12 to 18, no indexes for an accumulation of the drug in the blood could be found, when liposomes were given every four weeks.

L1 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB A review. Doxorubicin and other anthracyclines are an important class of agents for the treatment of early and advanced stage breast cancer, but produce substantial acute and chronic toxicities. One strategy for reducing anthracycline-associated toxicity is packaging them in liposomes. Liposomes are closed vesicular structures that envelop water-soluble mols. They may serve as vehicles for delivering cytotoxic agents more specifically to tumor, and limit exposure of normal tissues to the drug. Liposomal anthracyclines are more effective and less toxic in a number of preclin. models compared with conventional anthracyclines. Several liposomal anthracyclines have been extensively studied in humans with a variety of cancer types, including TLC D-99 (Myocet; The **Liposome** Company, Elan Corporation, Princeton, NJ), liposomal daunorubicin (Daunoxome; NeXstar Pharmaceuticals, Inc, San Dimas, CA), and pegylated liposomal doxorubicin (Doxil; Alza Pharmaceuticals, Palo Alto, CA, Caelyx; Schering Corporation, Kenilworth, NJ). Although none of these agents are currently approved for the treatment of breast cancer in the United States, the liposomal doxorubicin prepns. seem to have comparable activity and less cardiac toxicity than conventional doxorubicin. Furthermore, they have been safely combined with other cytotoxic agents, including cyclophosphamide, 5-fluorouracil, **vinorelbine**, paclitaxel, and

docetaxel. Further studies will be required to determine their role in the treatment of breast cancer.

L1 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g. , vincristine, to a mammal with a lymphoma. Liposomeencapsulated vincristine (vincristine sulfate liposome injection) was prepared using a six vial kit wherein vials 1 and 2 contained vincristine sulfate solution (1mg/mL Vincasar PFS)in buffer comprising mannitol and sodium acetate, pH 4.5-4.7, vial 3 contained empty liposomes (100mg/mL Sphingomyelin/Cholesterol liposomes, at a ratio of between about 60/40 to 50/50, or more preferably 55/45 mol%/o/mol%) in buffer comprising 300 mM citrate at pH 4.0, vials 4 and 5 contained an alkaline phosphate buffer (14.2 mg/mL dibasic sodium phosphate hepta hydrate), and vial 6 was an empty, sterile vial.

L1 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB In this study, tumor uptake and clearance of doxorubicin were determined for two formulations of the drug: the free form in aqueous solution and the encapsulated form in polyethylene glycol-coated (pegylated, STEALTH) liposomes composed of cholesterol/hydrogenated soy phosphatidylcholine/polyethylene glycol-distearoyl-phosphatidyl-ethanolamine (Doxil). The detns. used confocal laser scanning microscopy in a pancreatic carcinoma model in nude mice. The movement of pegylated liposomes containing doxorubicin from blood vessels into tumors was studied using confocal microscopy combined with autoradiog. of liposomes containing a tritium-labeled phospholipid. Laser microscopy measurements showed that the **liposome**-encapsulated doxorubicin remained in the tumor longer than the free drug and produced a six-fold increase in the area under the concentration-time curve (AUC). Autoradiog. showed that the extravasated tritium-labeled lipid had entered the nuclei as well as the cytoplasm of tumor cells. The authors also compared the therapeutic effects of i.v. cisplatin, doxorubicin hydrochloride, vincristine sulfate, and **vinorelbine** tartrate, each in the aqueous free form or encapsulated in pegylated liposomes. In this pancreatic carcinoma model, the **liposome**-encapsulated drugs were all more effective than the free drugs in inhibiting tumor growth and in producing cures. Except for cisplatin, all of the free drugs had toxic systemic side effects indicated by an average weight loss of 3 to 5%, which was recovered by 2 to 4 wk after the last treatment. The **liposome**-encapsulated drugs did not cause weight loss.

L1 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB Reagents for use in preparing a therapeutic liposome composition sensitized to a target cell are described. The reagents include a liposomal composition composed of pre-formed liposomes having an entrapped therapeutic agent and a plurality of targeting conjugates composed of a lipid, a hydrophilic polymer and a targeting ligand. The therapeutic, target-cell sensitized liposome composition is formed by incubating the liposomal composition with a selected conjugate. Liposomes were prepared by mixing partially hydrogenated soybean phosphatiylcholin, cholesterol, and mPEG-DSPE at a molar ratio of 55:40:3 in chloroform and/or methanol in a round bottom flask. The solvents were removed and the dried lipid film produced was hydrated with a buffer to produce large multilamellar vesicles. An anti-E-selectin Fab fragment was conjugated to PEG-DSPE to form a targeting conjugate. An adequate amount of the Fab-PEG-DSPE conjugate was added to a suspension of the above liposomes and incubated overnight at room temperature for the insertion of the conjugate into preformed liposomes.

L1 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AB The compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration was studied. Five milliliters of doxorubicin hydrochloride liposome injection 0.4 mg/mL in 5% dextrose injection was combined with 5 mL of each of 82 other drugs in 5% dextrose injection or, if necessary to avoid incompatibilities with the diluent, 0.9% sodium chloride injection. The combinations were examined

with the unaided eye in fluorescent light and in high-intensity monodirectional light to enhance visualization of small particles and low-level turbidity. The turbidity of each combination was measured as well. Particle sizing and counting were performed on selected combinations. Evaluations were performed initially and at one and four hours. All combinations were stored at room temperature (.apprx.23 °C). Most of the test drugs were compatible with doxorubicin hydrochloride liposome injection during the four-hour observation period. However, practitioners should be cautious in administering any drug simultaneously with doxorubicin hydrochloride liposome injection until the integrity of the liposomes can be verified. Eighteen drugs exhibited unacceptable increases or decreases in measured turbidity or particulate formation within four hours. During simulated Y-site administration, doxorubicin hydrochloride 0.4 mg/mL (as the liposomal injection) in 5% dextrose injection was compatible with 64 of 82 other drugs for four hours at .apprx.23 °C and was incompatible with 18 of the test drugs.

=> d l1 1-19

L1 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:527207 CAPLUS
DN 143:48144
TI Process for producing liposome suspension and product containing liposome suspension produced thereby
IN Hu, Yu-Fang; Huang, Yao-Kun; Lin, Chun-Chou; Kan, Chi-Liang
PA Taiwan
SO U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005129750	A1	20050616	US 2003-734272	20031215
	CN 1568939	A	20050126	CN 2003-178458	20030717
	US 2005129752	A1	20050616	US 2004-957027	20041001
PRAI	CN 2003-3178458	A	20030717		
	US 2003-734272	A2	20031215		

L1 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:404691 CAPLUS
DN 143:353081
TI Optimization and characterization of a sphingomyelin/cholesterol **liposome** formulation of **vinorelbine** with promising antitumor activity
AU Semple, Sean C.; Leone, Robert; Wang, Jinfang; Leng, Esther C.; Klimuk, Sandra K.; Eisenhardt, Merete L.; Yuan, Zuan-Ning; Edwards, Katarina; Maurer, Norbert; Hope, Michael J.; Cullis, Pieter R.; Ahkong, Quet-Fah
CS Inex Pharmaceuticals Corporation, Burnaby, BC, V5J 5J8, Can.
SO Journal of Pharmaceutical Sciences (2005), 94(5), 1024-1038
CODEN: JPMSAE; ISSN: 0022-3549
PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:384612 CAPLUS
DN 143:353013
TI **Liposome**-encapsulated vincristine, vinblastine and **vinorelbine**: a comparative study of drug loading and retention
AU Zhigaltsev, Igor V.; Maurer, Norbert; Akhong, Quet-Fah; Leone, Robert; Leng, Esther; Wang, Jinfang; Semple, Sean C.; Cullis, Pieter R.
CS Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of British Columbia, Vancouver, BC, V6T 1Z3, Can.
SO Journal of Controlled Release (2005), 104(1), 103-111
CODEN: JCREEC; ISSN: 0168-3659

PB Elsevier B.V.
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:120746 CAPLUS
DN 142:170061
TI Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia
IN Saltman, David
PA Inex Pharmaceuticals Corporation, Can.
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005011698	A1	20050210	WO 2004-CA1038	20040723

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-490789P P 20030728
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:964831 CAPLUS
DN 141:410944
TI Preparation of piperidinyl targeting compounds that selectively bind integrins
IN De Corte. Bart; Kinney, William A.; Maryanoff, Bruce E.; Ghosh, Shyamali; Liu, Li
PA USA
SO U.S. Pat. Appl. Publ., 160 pp., Cont.-in-part of U.S. Ser. No. 641,964.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004224986	A1	20041111	US 2004-782060	20040218
US 2004077684	A1	20040422	US 2003-641964	20030815
WO 2005082889	A1	20050909	WO 2004-US9465	20040329

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-404239P P 20020816
US 2003-641964 A2 20030815
US 2004-782060 A 20040218
OS MARPAT 141:410944

L1 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:699096 CAPLUS
DN 142:106732
TI Phase I Study of Doxil and Vinorelbine in Patients with Advanced Malignancies
AU Laufman, Leslie R.; Spiridonidis, C. Harris; Jones, Jacqueline J.; Rhodes, Virginia; Rossi, Karen; Wallace, Kelly
CS Hematology Oncology Consultants, Inc., Columbus, OH, 43235, USA
SO Cancer Investigation (2004), 22(3), 344-352
CODEN: CINVD7; ISSN: 0735-7907
PB Marcel Dekker, Inc.
DT Journal
LA English
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:403746 CAPLUS
DN 142:100157
TI Stealth liposomal vinca alkaloids (vinorelbine and vincristine) and in vitro studies on release by buffer and rat plasma
AU Demetzos, C.
CS Cancer Research Institute and Department of Pharmacology, University of California San Francisco, CA, 94143-0450, USA
SO Biomedical and Health Research (2002), 55(Drug Discovery and Design), 131-141
CODEN: BIHREN; ISSN: 0929-6743
PB IOS Press
DT Journal
LA English
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:310645 CAPLUS
DN 140:315054
TI Compositions and methods for treating cancer
IN Sarris, Andreas H.; Cabanillas, Fernando; Logan, Patricia M.; Burge, Clive T. R.; Goldie, James H.; Webb, Murray S.; Madden, Thomas D.; Semple, Sean C.; Ahkong, Quet F.; Klimuk, Sandra K.
PA Inex Pharmaceuticals Corporation, Can.; The University of Texas, MD Anderson Cancer Center
SO U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Pat. Appl. 2002 110,586.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004071768	A1	20040415	US 2003-407864	20030403
	US 6723338	B1	20040420	US 2000-541436	20000331
	US 2002110586	A1	20020815	US 2001-896812	20010629
	US 2004170678	A1	20040902	US 2004-788649	20040227
PRAI	US 1999-127444P	P	19990401		
	US 1999-137194P	P	19990602		
	US 2000-541436	A2	20000331		
	US 2000-215556P	P	20000630		
	US 2001-264616P	P	20010126		
	US 2001-896812	A2	20010629		

L1 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:173434 CAPLUS
DN 138:210345
TI Vinorelbine compositions and methods of use
IN Zhang, Jia-Ai; Ahmad, Imran
PA Neopharm, Inc., USA
SO PCT Int. Appl., 15 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003018018	A2	20030306	WO 2002-US26907	20020823
WO 2003018018	A3	20030501		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004228911	A1	20041118	US 2004-786866	20040224
PRAI US 2001-314959P	P	20010824		
WO 2002-US26907	A1	20020823		

L1 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:926961 CAPLUS
DN 139:254812
TI Unexpected Low Efficacy of Stealth Liposomal Doxorubicin (Caelyx) and Vinorelbine in Metastatic Breast Cancer
AU Rimassa, Lorenza; Carnaghi, Carlo; Garassino, Isabella; Salvini, Piermario; Ginanni, Valeria; Gullo, Giuseppe; Morenghi, Emanuela; Santoro, Armando
CS Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano (MI), Italy
SO Breast Cancer Research and Treatment (2003), 77(2), 185-188
CODEN: BCTRD6; ISSN: 0167-6806
PB Kluwer Academic Publishers
DT Journal
LA English
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:868715 CAPLUS
DN 137:346164
TI Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
IN Flowers, Clay; Saltman, David; Tam, Patrick M. S.; Burge, Clive T. R.; Harasym, Troy O.
PA Inex Pharmaceuticals Corporation, Can.
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002089772	A1	20021114	WO 2002-US14608	20020509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003082228	A1	20030501	US 2002-143545	20020509
PRAI US 2001-289935P	P	20010509		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:315065 CAPLUS
DN 136:337344
TI Methods of high-throughput screening for internalizing ligands or antibodies and their receptors
IN Marks, James D.; Nielsen, Ulrik B.; Kirpotin, Dmitri B.
PA The Regents of the University of California, USA
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002033044	A2	20020425	WO 2001-US32311	20011017
	WO 2002033044	A3	20030116		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002182643	A1	20021205	US 2001-981636	20011016
	CA 2425602	AA	20020425	CA 2001-2425602	20011017
	EP 1327149	A2	20030716	EP 2001-981656	20011017
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004526940	T2	20040902	JP 2002-536414	20011017
PRAI	US 2000-241279P	P	20001018		
	WO 2001-US32311	W	20011017		

L1 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:206165 CAPLUS
DN 136:334631
TI The role of gemcitabine-based doublets in the management of ovarian carcinoma
AU Thigpen, Tate
CS Division of Oncology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS, 39216, USA
SO Seminars in Oncology (2002), 29(1, Suppl. 1), 11-16
CODEN: SOLGAV; ISSN: 0093-7754
PB W. B. Saunders Co.
DT Journal; General Review
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:800436 CAPLUS
DN 136:95725
TI Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP)
AU Linkesch, W.; Weger, M.; Eder, I.; Auner, H. W.; Pernegg, C.; Kraule, C.; Czejka, M. J.
CS Div. of Haematology, Dep. of Medicine, University Clinic of Graz, Austria
SO European Journal of Drug Metabolism and Pharmacokinetics (2001), 26(3), 179-184
CODEN: EJDPD2; ISSN: 0378-7966
PB Medecine et Hygiene
DT Journal
LA English
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:715320 CAPLUS
DN 136:31171
TI Liposomal anthracyclines for breast cancer
AU Sparano, Joseph A.; Winer, Eric P.
CS Department of Oncology, Montefiore Medical Center-Weiler Division, Bronx, NY, 10461, USA
SO Seminars in Oncology (2001), 28(4, Suppl. 12), 32-40
CODEN: SOLGAV; ISSN: 0093-7754
PB W. B. Saunders Co.
DT Journal; General Review
LA English
RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:725434 CAPLUS
DN 133:301169
TI Compositions containing liposome-encapsulated vinca alkaloids and methods for treating lymphoma or leukemia
IN Sarris, Andreas H.; Cabanillas, Fernando; Logan, Patricia M.; Burge, Clive T. R.; Goldie, James H.; Webb, Murray S.
PA Inex Pharmaceuticals Corp., Can.
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000059473	A1	20001012	WO 2000-US8669	20000331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2366787	AA	20001012	CA 2000-2366787	20000331
AU 2000040606	A5	20001023	AU 2000-40606	20000331
AU 777572	B2	20041021		
BR 2000009448	A	20020108	BR 2000-9448	20000331
EP 1169021	A1	20020109	EP 2000-920004	20000331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002541088	T2	20021203	JP 2000-609037	20000331
PRAI US 1999-127444P	P	19990401		
US 1999-137194P	P	19990602		
WO 2000-US8669	W	20000331		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:309308 CAPLUS
DN 133:213015
TI Tumor uptake and therapeutic effects of drugs encapsulated in long-circulating pegylated stealth liposomes
AU Colbern, Gail; Vaage, Jan; Donovan, Dorothy; Uster, Paul; Working, Peter
CS ALZA Corporation, Mountain View, CA, 94039, USA
SO Journal of Liposome Research (2000), 10(1), 81-92
CODEN: JLREE7; ISSN: 0898-2104
PB Marcel Dekker, Inc.
DT Journal
LA English
RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:283948 CAPLUS
DN 132:313704
TI Therapeutic liposome composition and method of preparation
IN Allen, Theresa M.; Uster, Paul; Martin, Francis J.; Zalipsky, Samuel
PA Sequus Pharmaceuticals, Inc., USA
SO U.S., 17 pp., Cont.-in-part of U.S. 5,891,469.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6056973	A	20000502	US 1998-138480	19980821
	CA 2505445	AA	19980423	CA 1997-2505445	19971010
	US 5891468	A	19990406	US 1997-949046	19971010
	EP 1214935	A2	20020619	EP 2002-76092	19971010
	EP 1214935	A3	20030618		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, AL				
	US 6316024	B1	20011113	US 2000-517224	20000302
	US 2001038851	A1	20011108	US 2001-876707	20010607
	AU 761204	B2	20030529	AU 2001-83637	20011025
	US 2002172711	A1	20021121	US 2001-16324	20011210
	US 6936272	B2	20050830		
	US 2003215490	A1	20031120	US 2002-115566	20020402
	US 2004191250	A1	20040930	US 2004-821018	20040407
	US 2004191307	A1	20040930	US 2004-821021	20040407
	US 2005136064	A1	20050623	US 2005-49848	20050202
	US 2005169980	A1	20050804	US 2005-50012	20050202
PRAI	US 1996-28269P	P	19961011		
	US 1997-949046	A2	19971010		
	AU 1997-49878	A3	19971010		
	CA 1997-2267904	A3	19971010		
	EP 1997-912775	A3	19971010		
	US 1998-138480	A3	19980821		
	US 2000-517224	A3	20000302		
	US 2001-876707	A1	20010607		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:795285 CAPLUS
DN 128:110395
TI Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration
AU Trissel, Lawrence A.; Gilbert, Doward L.; Martinez, Juan F.
CS Division of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA
SO American Journal of Health-System Pharmacy (1997), 54(23), 2708-2713
CODEN: AHSPEK; ISSN: 1079-2082
PB American Society of Health-System Pharmacists
DT Journal
LA English
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT